Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

III trial; and (ii) completing a high-value partnership for the CPP-109 program. With the addiction market potentially exceeding $1 billion and growing, we believe CPP-109 is very competitively positioned from a safety and efficacy perspective."

Mr. McEnany concluded, "As a shareholder with a significant personal investment in the Company, my interests are aligned with the interests and concerns of every shareholder. I am deeply committed to building a successful Company."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. Catalyst has also recently been granted worldwide rights to another patented drug by Northwestern University. The Company intends to pursue development of this drug for several indications, including stimulant addiction and epilepsy. For more information about the Company, go to www.c
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of 18,200,000 shares of its common stock in an ... of $11.00 per share, before underwriting discounts. J.P. Morgan, ... as joint book-running managers for the offering. Piper ... for the offering. Avanir has granted the underwriters a ...
(Date:9/23/2014)... 2014  Echo Therapeutics, Inc. (NASDAQ: ... that, as it believes that its current liquidity ... 30, 2014, it has suspended its product development, ... conserve its liquidity and capital resources. ... Echo,s current financial position, funding alternatives, and projected ...
(Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3Echo Therapeutics Suspends Operations To Conserve Liquidity 2Echo Therapeutics Suspends Operations To Conserve Liquidity 3Echo Therapeutics Suspends Operations To Conserve Liquidity 4Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2
... LAUSANNE, Switzerland, October 15 ... integrated molecular and,immunodiagnostics based on its proprietary micro-technology platform, ... financing round. The,Company raised EUR 10 million ( USD ... , The deal was led ...
... Ganey Associates, Inc. today announced a broad partnership with ... help measure and improve satisfaction and engagement among patients, ... on October 1, 2009. , HMA owns and operates ... licensed beds, in non-urban communities located throughout the United ...
Cached Medicine Technology:Biocartis Raises EUR10 Million in Series A Financing Round 2Biocartis Raises EUR10 Million in Series A Financing Round 3Press Ganey Partners With Health Management Associates 2
(Date:9/23/2014)... 24, 2014 Menopause can cause ... roughly half of women, menopause can trigger debilitating ... commonly associated with major depressive disorder. These ... disturbances, memory loss, and fatigue. While hormone ... effects and high cost make them an unsuitable ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 The ... moderate rate over the past five years. Growth in ... consciousness has encouraged Canadians to consume more fish and ... encouraged food retailers and food-service establishments to increase their ... industry revenue. Additionally, strong economic growth in much of ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... Diego, CA (PRWEB) September 23, 2014 ... daily regarding all the latest information from the FDA ... on September 5, that its Private Label Jalapeno Bagels ... and small stones. Publix Jalapeno Bagels were ... the bakery department. , Taking into consideration the ...
Breaking Medicine News(10 mins):Health News:Pristiq Discounts Now Available from MedicationDiscountCard.com To Help Ease Menopause Symptoms 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... American Cancer Society, the largest non-government, not-for-profit funding source ... 152 new national research and training grants totaling $50,717,000 ... The grants, primarily to early career researchers, cover a ... from whether cadmium exposure increases the risk of endometrial ...
... pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several ... treated as medical problems. They,ve been "medicalized." In the ... of Social Science and Medicine , Brandeis researchers ... and a handful of other common conditions on escalating ...
... Best ... specialize in the R&D and distribution of innovative ophtalmic products to compensate for presbyopia ... High Definition reading glasses named Varionet. , ... (PRWEB) May 17, 2010 -- Best Vision International (BVI) of ...
... , This release is available in ... The world,s biggest investigation on possible links between cell ... a Canadian scientist who collaborated on the Interphone International ... of Montreal and an epidemiologist at the University of ...
... ... (ARC) program makes cutting-edge nanomaterials processing equipment more accessible and valuable , ... Newton, MA ... Microfluidizer(R) high shear fluid processors, has initiated a formal collaboration program to further ...
... ... Treatment Helps Patients Reverse Sun Damage and Restore the Health of Their Skin without ... ... extensive sun damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. ...
Cached Medicine News:Health News:American Cancer Society awards 152 new research and training grants 2Health News:American Cancer Society awards 152 new research and training grants 3Health News:American Cancer Society awards 152 new research and training grants 4Health News:American Cancer Society awards 152 new research and training grants 5Health News:American Cancer Society awards 152 new research and training grants 6Health News:The cost of medicalizing human conditions 2Health News:Introducing a New Generation of Reading and Computer Glasses 2Health News:Introducing a New Generation of Reading and Computer Glasses 3Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 3Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 4Health News:Epione Reveals a ‘Bright' New Solution for Dull, Sun Damaged Skin 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: